https://www.selleckchem.com/pr....oducts/pf-06463922.h
Haematopoietic stem cell transplantation (HSCT) is the only curative option available for patients with thalassaemia major in India with increasing access to alternate donor transplantation for patients with no matched family donor. We aimed to analyse the impact of family and alternate donor HSCT on morbidity and mortality post-HSCT METHODS We conducted a retrospective study in the department between July 2007 and December 2018 where all children who underwent HSCT for thalassaemia major were included RESULTS A total of 264 childre
Like
Comment
Share
